Metrics as of 10/15/2026, 11:14 PM (Berlin time), refresh in progress.
Catalyst Pharmaceuticals Stock
Catalyst Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard John Daly
- Employees
- 182
- Market cap
- $3.9 B
- IPO
- 08/11/2006
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating in the Healthcare sector within the Biotechnology industry. Based in Coral Gables, USA, and listed on the NASDAQ since its IPO on November 8, 2006, the company was founded in 2002 and is led by CEO Richard John Daly. As a commercial-stage…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Catalyst Pharmaceuticals stock: price history
1D
+0.0%
1W
+0.0%
1M
+0.4%
6M
+34.7%
YTD
+34.9%
1Y
+49.9%
2Y
+85.9%
5Y
+466.4%
10Y
+4,011.0%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~25% weaker price swings than usual
Ask the agents about Catalyst Pharmaceuticals
Analyst assessment of Catalyst Pharmaceuticals
PRICE TARGET LOW
US$31.50
CONSENSUS
US$31.75
MEDIAN
US$31.75
PRICE TARGET HIGH
US$32.00
0
STRONG BUY
12
BUY
4
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 28/05/2026
Catalyst Pharmaceuticals stock metrics
P/E
17.49
P/B
3.8
EV/EBITDA
9.27
RETURN ON EQUITY
6.3%
NET MARGIN
42.7%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
94.4%
FLOAT SHARES
115,583,952
AVG. DAILY VOLUME (30D)
2,090,363
Insider transactions (SEC)
Andrews William T.
Daly Richard J
Del Carmen Jeffrey
DENKHAUS DONALD A
Elsbernd Brian
Institutional holders
Comparable stocks
Frequently asked questions about Catalyst Pharmaceuticals stock
What does Catalyst Pharmaceuticals do?
Catalyst Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard John Daly, the company employs around 182 people.
The IPO was on 08/11/2006; the stock trades on NASDAQ under the ticker CPRX.
What do analysts say about Catalyst Pharmaceuticals stock?
16 analysts rate the stock, the consensus is Buy (as of 28/05/2026).
The average price target is US$31.75, ranging from US$31.50 to US$32.00, with a median of US$31.75.
This is an external assessment, not a statement by Market Jury.
When does Catalyst Pharmaceuticals report next?
Around past earnings, price swings were roughly -25% stronger than usual.
Does Catalyst Pharmaceuticals pay a dividend?
No, Catalyst Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Catalyst Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Catalyst Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Catalyst Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.